Bilix Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
12
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$19.5M
- Investors
-
15
Bilix General Information
Description
Developer of PEGylated bilirubin nanoparticles designed to treat ischemia-reperfusion injury by reducing inflammation and oxidative stress. The company offers a nanoparticle-based therapy with demonstrated safety in early trials and a targeted application for cardiac surgery-associated acute kidney injury, enabling pharmaceutical companies, clinicians, and healthcare providers to address organ damage caused by interrupted and restored blood flow, improve surgical outcomes, and reduce the long-term burden of acute kidney injury.
Contact Information
Website
www.bilix.comCorporate Office
- Building C, 338 Gwanggyojungang-ro, Suji-gu
- Suite 604
- Yongin, Gyeonggi 16942
- South Korea
Corporate Office
- Building C, 338 Gwanggyojungang-ro, Suji-gu
- Suite 604
- Yongin, Gyeonggi 16942
- South Korea
Bilix Timeline
Bilix Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC (Series B) | 10-Dec-2025 | $19.5M | Completed | Clinical Trials - Phase 2 | ||
| 6. Later Stage VC | 29-Jul-2025 | Completed | Clinical Trials - Phase 2 | |||
| 5. Accelerator/Incubator | 30-Jun-2025 | Completed | Clinical Trials - Phase 2 | |||
| 4. Accelerator/Incubator | 01-Aug-2024 | Completed | Clinical Trials - Phase 2 | |||
| 3. Accelerator/Incubator | Completed | Clinical Trials - Phase 2 | ||||
| 2. Seed Round | 01-Oct-2021 | $2.13K | $17.7K | Completed | Clinical Trials - Phase 2 | |
| 1. Early Stage VC (Series A) | 24-May-2021 | $15.6K | $15.6K | Completed | Clinical Trials - Phase 2 |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Bilix Comparisons
Industry
Financing
Details
Bilix Competitors (13)
One of Bilix’s 13 competitors is Renibus Therapeutics, a Venture Capital-Backed company based in Southlake, TX.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Renibus Therapeutics | Venture Capital-Backed | Southlake, TX | ||||
| Arch BioPartners | Corporation | Toronto, Canada | ||||
| Argenx | Formerly VC-backed | Zwijnaarde, Belgium | ||||
| Alloksys Life Sciences | Corporate Backed or Acquired | Wageningen, Netherlands | ||||
| Mission Therapeutics | Venture Capital-Backed | Cambridge, United Kingdom |
Bilix Patents
Bilix Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024186151-A1 | Pharmaceutical composition for preventing or treating ischemia reperfusion injury | Inactive | 08-Mar-2023 | ||
| JP-2025525431-A | Pharmaceutical composition containing pegylated bilirubin for preventing or treating inflammatory diseases | Active | 05-Jul-2022 | ||
| EP-4552640-A1 | Pharmaceutical composition for preventing or treating inflammatory diseases comprising pegylated bilirubin | Pending | 05-Jul-2022 | ||
| EP-4552640-A4 | Pharmaceutical composition for preventing or treating inflammatory diseases comprising pegylated bilirubin | Pending | 05-Jul-2022 | ||
| US-20260000600-A1 | Pharmaceutical composition for preventing or treating inflammatory diseases comprising pegylated bilirubin | Pending | 05-Jul-2022 | A61K8/86 |
Bilix Signals
Bilix Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| iM Investment Partners | Corporate Venture Capital | Minority | ||
| BiiG WAVE | Accelerator/Incubator | |||
| Korea Venture Business Association | Accelerator/Incubator | |||
| Alpen Route Asset Management | Venture Capital | Minority | ||
| DS Capital | Asset Manager | Minority |
Bilix FAQs
-
When was Bilix founded?
Bilix was founded in 2018.
-
Where is Bilix headquartered?
Bilix is headquartered in Yongin, South Korea.
-
What is the size of Bilix?
Bilix has 12 total employees.
-
What industry is Bilix in?
Bilix’s primary industry is Drug Discovery.
-
Is Bilix a private or public company?
Bilix is a Private company.
-
What is the current valuation of Bilix?
The current valuation of Bilix is .
-
What is Bilix’s current revenue?
The current revenue for Bilix is .
-
How much funding has Bilix raised over time?
Bilix has raised $29.5M.
-
Who are Bilix’s investors?
iM Investment Partners, BiiG WAVE, Korea Venture Business Association, Alpen Route Asset Management, and DS Capital are 5 of 15 investors who have invested in Bilix.
-
Who are Bilix’s competitors?
Renibus Therapeutics, Arch BioPartners, Argenx, Alloksys Life Sciences, and Mission Therapeutics are some of the 13 competitors of Bilix.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process